Jo et al. [54] found frequent RASSF1A methylation in cases with FIGO stage III and IV, lymph invasion and poorly-differentiated cancer and a five-year survival rate of 97.0% (p = 0.039) in patients with no RASSF1A methylation compared with 77.8% in those with RASSF1A methylation. Here, RASSF1 is linked to cancer.